Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

T6580

Sigma-Aldrich

Triflusal

≥98% (HPLC), powder

Synonym(s):

Triflusal, α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
¥11,220

¥11,220


Check Cart for Availability

Request a Bulk Order

Select a Size

Change View
5 MG
¥11,220

About This Item

Empirical Formula (Hill Notation):
C10H7F3O4
CAS Number:
Molecular Weight:
248.16
EC Number:
UNSPSC Code:
12352200
NACRES:
NA.25

¥11,220


Check Cart for Availability

Request a Bulk Order

Assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: >30 mg/mL

originator

Uriach

storage temp.

2-8°C

SMILES string

FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C

InChI

1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)

InChI key

RMWVZGDJPAKBDE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.

Features and Benefits

This compound was developed by Uriach. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

T6580-BULK:
T6580-25MG:
T6580-VAR:
T6580-5MG:


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Teodor Adrian Enache et al.
Combinatorial chemistry & high throughput screening, 13(7), 569-577 (2010-04-21)
The electrochemical behavior of triflusal (TRF) and aspirin (ASA), before and after hydrolysis in water and in alkaline medium using two different electrode surfaces, glassy carbon and boron doped diamond, was study by differential pulse voltammetry over a wide pH
Yingying Huang et al.
Biomaterials, 31(15), 4382-4391 (2010-03-02)
This study reports on a dual drug-eluting stent (DDES) that has an anti-proliferative and an anti-thrombotic in a biodegradable polymer-coated onto a cobalt-chromium stent. The DDES was prepared by spray coating the bare metal stent with a biodegradable polymer loaded
Iñaki Izquierdo et al.
Arzneimittel-Forschung, 60(1), 36-41 (2010-02-27)
Triflusal (CAS 322-79-2) is an antiplatelet agent that irreversibly acetylates cyclooxygenase isoform 1 (COX-1) and therefore inhibits thromboxane biosynthesis. The main metabolite of triflusal, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), possesses also antiaggregant activity. Recently a new oral 600 mg (10 ml)
Emilio García Quetglas et al.
Arzneimittel-Forschung, 58(6), 283-287 (2008-08-06)
Triflusal (CAS 322-79-2) is an antiplatelet agent related to salicylates used in several European and Latin American countries in the treatment of cardiovascular diseases. The aim of this paper was to evaluate the bioequivalence of triflusal derived from two preparations
Jung-Won Suh et al.
International heart journal, 50(6), 701-709 (2009-12-03)
Triflusal is a derivative of acetylsalicylic acid but it exhibits different pharmacological and pharmacokinetic properties. The object of this study was to evaluate the efficacy of additional use of triflusal in patients who underwent drug-eluting stent implantation. First, we prospectively

Articles

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service